Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zai LabSTU:1ZLB -2.87%68 Market Cap is €1,953.8 Mil as of Jul. 15, 2026. GuruFocus rates STU:1ZLB with a GF Score™ of 68/100 and a GF Value™ of €2.65 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,423 Biotechnology companies, Zai Lab ranks better than 89.32% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Zai Lab's share price for the quarter that ended in Mar. 2026 was €1.54. Zai Lab's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 1,110.2 Mil. Therefore, Zai Lab's market cap for the quarter that ended in Mar. 2026 was €1,709.8 Mil.
Zai Lab's quarterly market cap
declined
from Sep. 2025 (€3,162.8 Mil) to Dec. 2025 (€1,626.4 Mil) but then
increased
from Dec. 2025 (€1,626.4 Mil) to Mar. 2026 (€1,709.8 Mil).
Zai Lab's annual market cap
increased
from Dec. 2023 (€2,352.8 Mil) to Dec. 2024 (€2,758.9 Mil) but then
declined
from Dec. 2024 (€2,758.9 Mil) to Dec. 2025 (€1,626.4 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Zai Lab's Enterprise Value for Today is €1,576.7 Mil.
Zai Lab (STU:1ZLB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Zai Lab Market Cap Related Terms
Zai Lab Market Cap Historical Data
* Premium members only.
The historical data trend for Zai Lab's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1ZLB vs STOK, ADMA, VRDN: Market Cap Comparison
For the Biotechnology subindustry, Zai Lab's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zai Lab Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zai Lab's Market Cap distribution charts can be found below:
* The bar in red indicates where Zai Lab's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Zai Lab's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab (STU:1ZLB) has a Market Cap of €1,953.8 Mil as of Jul. 15, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zai Lab and its competitors. According to the industry distribution chart, Zai Lab ranks #152 out of 1423 companies in the Biotechnology industry, placing it in the top 10.7%.
Is Zai Lab's Market Cap too high?
Zai Lab's current Market Cap is €1,953.8 Mil. Based on the distribution chart, Zai Lab ranks #152 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zai Lab has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's Market Cap compare to STOK and ADMA?
According to the Biotechnology industry distribution chart, Zai Lab ranks #152 out of 1423 companies for Market Cap. This places Zai Lab in the top 11% of its industry — outperforming the majority of peers. The industry median Market Cap is 114.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.24, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zai Lab and its competitors. For the Biotechnology industry, the median Market Cap is 114.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zai Lab's current Market Cap is €1,953.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (STU:1ZLB) is currently considered Possible Value Trap. The stock's GF Value™ is €2.65, compared to a current price of €1.69 — trading 36.2% below its estimated fair value. The current Market Cap is €1,953.8 Mil. Zai Lab's overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Zai Lab (STU:1ZLB), the current Market Cap is €1,953.8 Mil as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zai Lab (STU:1ZLB) Overvalued in 2026?
Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued.
The current stock price of €1.69 is trading 36.2% below its estimated GF Value™ of €2.65.
GuruFocus considers Zai Lab to be Possible Value Trap.
Key valuation signals for STU:1ZLB:
Market Cap: €1,953.8 Mil
GF Value™: €2.65 vs. price of €1.69 (36.2% below fair value)
No single metric tells the full story. See the STU:1ZLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
68GF Score
Get the complete analysis for STU:1ZLB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1ZLB has been successfully added to your 
